Adverum Biotechnologies Inc (ADVM)
6.04
+0.29
(+5.04%)
USD |
NASDAQ |
Nov 22, 16:00
6.05
+0.01
(+0.17%)
After-Hours: 20:00
Adverum Biotechnologies Cash from Operations (Quarterly): -21.12M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -21.12M |
| June 30, 2024 | -19.84M |
| March 31, 2024 | -23.24M |
| December 31, 2023 | -21.33M |
| September 30, 2023 | -23.91M |
| June 30, 2023 | -23.25M |
| March 31, 2023 | -22.41M |
| December 31, 2022 | -18.48M |
| September 30, 2022 | -31.81M |
| June 30, 2022 | -28.88M |
| March 31, 2022 | -28.93M |
| December 31, 2021 | -25.82M |
| September 30, 2021 | -25.80M |
| June 30, 2021 | -33.92M |
| March 31, 2021 | -22.30M |
| December 31, 2020 | -22.22M |
| September 30, 2020 | -26.54M |
| June 30, 2020 | -16.91M |
| March 31, 2020 | -13.62M |
| December 31, 2019 | -14.84M |
| September 30, 2019 | -9.53M |
| June 30, 2019 | -11.59M |
| March 31, 2019 | -13.22M |
| December 31, 2018 | -12.73M |
| Date | Value |
|---|---|
| September 30, 2018 | -16.90M |
| June 30, 2018 | -11.35M |
| March 31, 2018 | -12.98M |
| December 31, 2017 | -12.20M |
| September 30, 2017 | -9.985M |
| June 30, 2017 | -11.42M |
| March 31, 2017 | -11.82M |
| December 31, 2016 | -8.342M |
| September 30, 2016 | -9.647M |
| June 30, 2016 | -8.224M |
| March 31, 2016 | -12.15M |
| December 31, 2015 | -9.126M |
| September 30, 2015 | -9.22M |
| June 30, 2015 | -9.25M |
| March 31, 2015 | -7.742M |
| December 31, 2014 | -5.055M |
| September 30, 2014 | -4.973M |
| June 30, 2014 | 5.727M |
| March 31, 2014 | -1.347M |
| December 31, 2013 | -0.721M |
| September 30, 2013 | -0.59M |
| June 30, 2013 | -0.72M |
| March 31, 2013 | -0.144M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-33.92M
Minimum
Jun 2021
-13.62M
Maximum
Mar 2020
-23.26M
Average
-22.83M
Median
Cash from Operations (Quarterly) Benchmarks
| EyePoint Pharmaceuticals Inc | -39.03M |
| Cassava Sciences Inc | -18.30M |
| Regenxbio Inc | -40.55M |
| Editas Medicine Inc | -52.59M |
| Apellis Pharmaceuticals Inc | 34.10M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -13.35M |
| Free Cash Flow | -86.06M |
| Free Cash Flow Per Share (Quarterly) | -1.022 |
| Free Cash Flow to Equity (Quarterly) | -21.34M |
| Free Cash Flow to Firm (Quarterly) | -21.34M |
| Free Cash Flow Yield | -83.41% |